Date: 2013-07-19
Type of information: R&D agreement
Compound:
Company: BiogenIdec (USA - MA) The University of Edinburgh (UK)
Therapeutic area: Autoimmune diseases – Neurodegenerative diseases - Neuromuscular diseases
Type agreement: R&D
Action mechanism:
Disease: multiple sclerosis, motor neurone disease
Details: * On July 19, 2013, the University of Edinburgh has announced that experts from the University and the Massachusetts-based biotechnology company Biogen Idec will work together to seek greater insight into the cell processes behind multiple sclerosis and motor neurone disease. This will include identifying drug compounds that could potentially be used as treatments. The three-year collaboration will combine the University’s expertise in translational medicine - which develops laboratory discoveries into treatments for patients - with Biogen Idec’s strength in drug discovery and development. Clinicians and scientists, based at Edinburgh BioQuarter -Scotland’s flagship lifesciences project - will be involved in the project, which will draw on the University’s strength in neuroscience, stem cell research and regeneration.
Financial terms:
Latest news:
